overview
The infant-specific artemether-lumefantrine prequalified by the World Health Organization is a significant step toward the treatment of malaria in newborns and infants. The acceptance should have a strong impact on the mortality rate in the high-burden areas, especially sub-Saharan Africa.
Infant-specific First Treatment.
This is the inaugural malaria drug designed to be utilized in newborns and infants that are very young. Previously, medications were prescribed based on doses targeted to older children, which augmented the chances of medication mistakes, side effects and toxicity. The new formula enhances the accuracy of dosing, safety, and therapeutic effects of the drug in this susceptible age group.
WHO Prequalification is important.
WHO prequalification confirms that a medicine is of global quality, safety and efficacy. It facilitates government and international agencies procurement in the context of public health programmes, particularly in those countries whose regulatory capacity is limited. This expedites accessibility, scale-up in malaria-prone areas.
Global Malaria Burden
Malaria is a significant health issue. It had approximately 282 million cases, and approximately 610 000 deaths in the world in 2024, with almost all of them in Africa. The number of children aged below five contributes to almost three-fourths of death caused by malaria, a factor that highlights the requirement of age-specific treatments.
Current Problems and Future.
Drug and insecticide resistance, gaps in diagnosis, and lack of funding limits progress. But more recent tools; vaccines, better control of vectors, better diagnostics, and now infant-specific treatments, are reinforcing control measures. Long-term elimination goals are only attained through long-term political dedication and funding.
Exam-Focused Points
- WHO prequalified artemether-lumefantrine infant specific.
- The first antimalarial designed to treat newborn and infants.
- Prequalification allows international buying and increased availability.
- Most of the malaria burden in sub-Saharan Africa.
- The highest number of deaths due to malaria is on children below the age of five.
MCQ
Q. Why is WHO prequalification of medicines important?
A. To remedy drug prices worldwide.
B. To qualify quality, safety and efficacy towards global acquisition.
C. To encourage homegrown pharmaceutical firms.
D. To control infrastructure in hospitals.
Answer: B
Explanation: The prequalification of medicines by WHO is a method of ensuring that governments and health agencies across the world can purchase drugs that are of an international standard, safe, and effective.